Understanding the transformative impact of ICH E6(R3) guidelines on clinical trial oversight and quality management.

Understanding the transformative impact of ICH E6(R3) guidelines on clinical trial oversight and quality management.
Understand key Windsor Framework changes for UK pharmacovigilance in 2025 and how MAHs can stay compliant under new MHRA rules
The FDA’s new CSA guidance aims to streamline CSV by promoting risk-based validation, reducing documentation, and enhancing quality and patient safety.
Explore how a new validation model helps ensure data integrity in decentralized clinical trials, reducing compliance risk and enabling inspection readiness across complex systems.
Learn key strategies to ensure inspection readiness in clinical trials, from TMF accuracy to sponsor oversight, SME preparation, and quality-controlled documentation.
Discover how ADAMAS ensures long-term, inspection-ready access to audit records and documentation, supporting clients with reliable, compliant records retention.
Explore how decentralized clinical trials improve patient recruitment and retention through digital innovation—while a new validation model ensures data integrity, compliance, and inspection readiness.
Learn how ADAMAS ensures industry-leading data privacy and cybersecurity compliance through robust policies, secure platforms, and expert oversight—protecting clients against evolving risks.
Understand how implementing KRIs and QTLs is essential to meeting ICH E6(R2) requirements and preparing for the risk-based focus of the upcoming ICH E6(R3) revision.
Discover how ADAMAS delivers enterprise-grade QA compliance with advanced data security, privacy protocols, and a robust Quality Management System that exceeds industry standards.